Randomized trials comparing alfaxalone with propofol for canine cesarean induction: better neonatal Apgar scores with alfaxalone, similar puppy survival.

A randomized trial found 80% survival with an outpatient parvovirus protocol versus 90% hospitalized; field series and CPMA data inform the approach.

Oclacitinib cut atopic pruritus within 24 h and, at 2 mg/kg, lokivetmab separated from placebo on owner-assessed pruritus from day 1 through day 49 in pivotal RCTs; direct head-to-head evidence remains thin.

The metronidazole dose used in the Langlois placebo-controlled trial of acute diarrhea in dogs, and the mixed, modest evidence that it speeds resolution at all.

RECOVER CPR guidelines for dogs: compression rate and depth, ventilation, drug therapy, monitoring, post-arrest care, and what the 2024 update changed.

Canine xylitol toxicity: insulin-mediated hypoglycemia and hepatopathy, with decontamination, monitoring, and prognosis from published case series.

In a 2023 JVIM field trial, once-daily bexagliflozin achieved treatment success in 84% of newly diagnosed diabetic cats, but euglycemic DKA occurred in 4 of 84.

A 2026 JAVMA randomized controlled trial found lorazepam given after hospitalization was associated with zero urethral obstruction recurrences in male cats.

CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) is first-line for canine nodal lymphoma: median survival 302–321 days; prednisone alone 50 days.

Evidence-based canine IMHA treatment protocol from the 2019 ACVIM consensus, with antithrombotics per the ACVECC CURATIVE guidelines.